Corium International Inc  

(Public, NASDAQ:CORI)   Watch this stock  
Find more results for CORI
6.98
+0.02 (0.29%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.98 - 6.98
52 week 4.30 - 8.49
Open 6.98
Vol / Avg. 112.00/4,219.00
Mkt cap 126.13M
P/E     -
Div/yield     -
EPS -0.80
Shares 18.07M
Beta     -
Inst. own 84%
May 11, 2015
Q2 2015 Corium International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 11, 2015
Corium International Inc at Leerink Global Healthcare Conference
Feb 10, 2015
Q1 2015 Corium International Inc Earnings Call
Feb 10, 2015
Q1 2015 Corium International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -69.21% -23.36%
Operating margin -52.12% -23.68%
EBITD margin - -17.40%
Return on average assets -40.13% -18.06%
Return on average equity -304.00% -
Employees 243 -
CDP Score - -

Address

235 Constitution Dr
MENLO PARK, CA 94025-1108
United States - Map
+1-650-2988012 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage its broad experience in transdermal and transmucosal delivery systems. The Company�s marketed products are Clonidine Transdermal Delivery System, or TDS, Fentanyl TDS and four Crest Advanced Seal Whitestrips products. Its transdermal technologies are MicroCor, a biodegradable microstructure patch technology for active delivery of proteins, peptides and vaccines large molecules that require active transport through the skin, and Corplex, a novel adhesive system and patch technology for delivery of small molecules that may otherwise be difficult to formulate and deliver.

Officers and directors

Peter D. .. President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Robert Breuil Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Parminder Singh Ph.D. Chief Technology Officer, Vice President - Research & Development
Age: 51
Bio & Compensation  - Reuters
Bhaskar Chaudhuri Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Ronald W. Eastman Director
Age: 62
Bio & Compensation  - Reuters
Phyllis I. Gardner M.D. Director
Age: 64
Bio & Compensation  - Reuters
Ivan P. Gergel M.D. Director
Age: 54
Bio & Compensation  - Reuters
Paul Goddard Ph.D. Director
Age: 65
Bio & Compensation  - Reuters